The Optimal Model of Reperfusion Injury Using H9c2 Transformed Cardiac Myoblasts
Overview
Affiliations
An model for ischemia/reperfusion injury has not been well-established. We hypothesized that this failure may be caused by serum deprivation, the use of glutamine-containing media, and absence of acidosis. Cell viability of H9c2 cells was significantly decreased by serum deprivation. In this condition, reperfusion damage was not observed even after simulating severe ischemia. However, when cells were cultured under 10% dialyzed FBS, cell viability was less affected compared to cells cultured under serum deprivation and reperfusion damage was observed after hypoxia for 24 h. Reperfusion damage after glucose or glutamine deprivation under hypoxia was not significantly different from that after hypoxia only. However, with both glucose and glutamine deprivation, reperfusion damage was significantly increased. After hypoxia with lactic acidosis, reperfusion damage was comparable with that after hypoxia with glucose and glutamine deprivation. Although high-passage H9c2 cells were more resistant to reperfusion damage than low-passage cells, reperfusion damage was observed especially after hypoxia and acidosis with glucose and glutamine deprivation. Cell death induced by reperfusion after hypoxia with acidosis was not prevented by apoptosis, autophagy, or necroptosis inhibitors, but significantly decreased by ferrostatin-1, a ferroptosis inhibitor, and deferoxamine, an iron chelator. These data suggested that in our SIR model, cell death due to reperfusion injury is likely to occur ferroptosis, which is related with ischemia/reperfusion-induced cell death . In conclusion, we established an optimal reperfusion injury model, in which ferroptotic cell death occurred by hypoxia and acidosis with or without glucose/glutamine deprivation under 10% dialyzed FBS.
Zhang X, Zhao P, Kuai J, Chang C, Yuan Q Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(1):166-172.
PMID: 38293988 PMC: 10878897. DOI: 10.12122/j.issn.1673-4254.2024.01.19.
Sahadevan R, Binoy A, Shajan I, Sadhukhan S RSC Adv. 2023; 13(42):29477-29488.
PMID: 37818277 PMC: 10561634. DOI: 10.1039/d3ra04527g.
Chen W, Zhang Y, Wang Z, Tan M, Lin J, Qian X Front Pharmacol. 2023; 14:1078205.
PMID: 36891270 PMC: 9986553. DOI: 10.3389/fphar.2023.1078205.
Emerging roles of ferroptosis in cardiovascular diseases.
Wang K, Chen X, Wang Y, Cheng X, Zhao Y, Zhou L Cell Death Discov. 2022; 8(1):394.
PMID: 36127318 PMC: 9488879. DOI: 10.1038/s41420-022-01183-2.
Basara G, Bahcecioglu G, Gulberk Ozcebe S, Ellis B, Ronan G, Zorlutuna P Biophys Rev (Melville). 2022; 3(3):031305.
PMID: 36091931 PMC: 9447372. DOI: 10.1063/5.0093399.